FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032057241> ?p ?o ?g. }

• W3032057241 abstract "12099 Background: CIPN is a common dose-limiting side effect of taxane and platinum chemotherapy. It is difficult for clinicians to predict who will experience CIPN before initiating chemotherapy, partly because the etiology of CIPN is poorly understood. Specifically, although inflammation putatively plays a role in CIPN, there is limited evidence of the role of inflammation in CIPN in humans. Here, we identified the strongest predictors of CIPN using variables measured before taxane or platinum chemotherapy, including serum inflammation. Methods: 143 sedentary patients with cancer (81% breast, 7% colon, 5% lung; 7% other; mean age 56 years) receiving taxane or platinum chemotherapy rated the severity of (a) numbness and tingling, and (b) hot/coldness in hands/feet on 0-10 point scales before and after their first 6 weeks of chemotherapy. Linear regression models were fit to predict CIPN symptom severity at 6 weeks using variables related to inflammation (serum IL-1β, IL-6, IL-8, IL-10, IFN-γ, sTNFR1; 69 patients who gave blood), clinical factors (cancer stage, baseline neuropathy, fatigue, anxiety, depression, using diabetes medications), behavior (daily pedometer steps), and demographics (age, race) measured before chemotherapy. The final model was identified by the smallest AIC goodness of fit. Results: The strongest pre-chemotherapy predictors of numbness and tingling after 6 weeks of taxane and/or platinum chemotherapy were worse patient-reported fatigue/anxiety/depression (explaining 25% of variance), platinum chemotherapy (7%), and older age (5%). The strongest predictors of hot/coldness in hands/feet included worse baseline neuropathy (13%), platinum chemotherapy (8%), and fatigue/anxiety/depression (6%). In the 69 patients with serum data, a more pro-inflammatory state was a risk factor for CIPN as higher levels of pro-inflammatory IL-1β (7%) predicted numbness/tingling, and lower levels of anti-inflammatory IL-10 (7%) predicted hot/coldness in hands/feet. Conclusions: The strongest pre-chemotherapy predictors of CIPN included worse fatigue/anxiety/depression and platinum chemotherapy in this sedentary population of cancer patients (mostly breast). A pro-inflammatory state before chemotherapy may also increase risk for CIPN, suggesting that inflammation may underlie the etiology of CIPN in humans. Clinicians should consider assessing these factors to inform the patient’s risk for CIPN. Funding: NCI UG1CA189961, NCI K07 K07CA221931, T32CA102618. Clinical trial information: NCT00924651 ." @default.
• W3032057241 created "2020-06-05" @default.
• W3032057241 creator A5000630808 @default.
• W3032057241 creator A5003724529 @default.
• W3032057241 creator A5025793579 @default.
• W3032057241 creator A5028996821 @default.
• W3032057241 creator A5031810299 @default.
• W3032057241 creator A5034225982 @default.
• W3032057241 creator A5037521018 @default.
• W3032057241 creator A5048210530 @default.
• W3032057241 creator A5060693199 @default.
• W3032057241 creator A5079546510 @default.
• W3032057241 creator A5081387413 @default.
• W3032057241 creator A5090143035 @default.
• W3032057241 date "2020-05-20" @default.
• W3032057241 modified "2023-09-26" @default.
• W3032057241 title "Inflammatory and clinical risk factors for chemotherapy-induced peripheral neuropathy (CIPN): A nationwide longitudinal study in 143 cancer patients during chemotherapy." @default.
• W3032057241 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.12099" @default.
• W3032057241 hasPublicationYear "2020" @default.
• W3032057241 type Work @default.
• W3032057241 sameAs 3032057241 @default.
• W3032057241 citedByCount "0" @default.
• W3032057241 crossrefType "journal-article" @default.
• W3032057241 hasAuthorship W3032057241A5000630808 @default.
• W3032057241 hasAuthorship W3032057241A5003724529 @default.
• W3032057241 hasAuthorship W3032057241A5025793579 @default.
• W3032057241 hasAuthorship W3032057241A5028996821 @default.
• W3032057241 hasAuthorship W3032057241A5031810299 @default.
• W3032057241 hasAuthorship W3032057241A5034225982 @default.
• W3032057241 hasAuthorship W3032057241A5037521018 @default.
• W3032057241 hasAuthorship W3032057241A5048210530 @default.
• W3032057241 hasAuthorship W3032057241A5060693199 @default.
• W3032057241 hasAuthorship W3032057241A5079546510 @default.
• W3032057241 hasAuthorship W3032057241A5081387413 @default.
• W3032057241 hasAuthorship W3032057241A5090143035 @default.
• W3032057241 hasConcept C121608353 @default.
• W3032057241 hasConcept C126322002 @default.
• W3032057241 hasConcept C134018914 @default.
• W3032057241 hasConcept C139719470 @default.
• W3032057241 hasConcept C141071460 @default.
• W3032057241 hasConcept C143998085 @default.
• W3032057241 hasConcept C162324750 @default.
• W3032057241 hasConcept C2776694085 @default.
• W3032057241 hasConcept C2776867660 @default.
• W3032057241 hasConcept C2777511904 @default.
• W3032057241 hasConcept C2779289229 @default.
• W3032057241 hasConcept C2779901536 @default.
• W3032057241 hasConcept C530470458 @default.
• W3032057241 hasConcept C555293320 @default.
• W3032057241 hasConcept C71924100 @default.
• W3032057241 hasConceptScore W3032057241C121608353 @default.
• W3032057241 hasConceptScore W3032057241C126322002 @default.
• W3032057241 hasConceptScore W3032057241C134018914 @default.
• W3032057241 hasConceptScore W3032057241C139719470 @default.
• W3032057241 hasConceptScore W3032057241C141071460 @default.
• W3032057241 hasConceptScore W3032057241C143998085 @default.
• W3032057241 hasConceptScore W3032057241C162324750 @default.
• W3032057241 hasConceptScore W3032057241C2776694085 @default.
• W3032057241 hasConceptScore W3032057241C2776867660 @default.
• W3032057241 hasConceptScore W3032057241C2777511904 @default.
• W3032057241 hasConceptScore W3032057241C2779289229 @default.
• W3032057241 hasConceptScore W3032057241C2779901536 @default.
• W3032057241 hasConceptScore W3032057241C530470458 @default.
• W3032057241 hasConceptScore W3032057241C555293320 @default.
• W3032057241 hasConceptScore W3032057241C71924100 @default.
• W3032057241 hasFunder F4320332161 @default.
• W3032057241 hasLocation W30320572411 @default.
• W3032057241 hasOpenAccess W3032057241 @default.
• W3032057241 hasPrimaryLocation W30320572411 @default.
• W3032057241 hasRelatedWork W12997972 @default.
• W3032057241 hasRelatedWork W14228319 @default.
• W3032057241 hasRelatedWork W17437393 @default.
• W3032057241 hasRelatedWork W19759200 @default.
• W3032057241 hasRelatedWork W20535288 @default.
• W3032057241 hasRelatedWork W20592577 @default.
• W3032057241 hasRelatedWork W2422317 @default.
• W3032057241 hasRelatedWork W6809237 @default.
• W3032057241 hasRelatedWork W7945670 @default.
• W3032057241 hasRelatedWork W9309986 @default.
• W3032057241 isParatext "false" @default.
• W3032057241 isRetracted "false" @default.
• W3032057241 magId "3032057241" @default.
• W3032057241 workType "article" @default.